Intensity Therapeutics, Inc. INTS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2023 · data as of November 13, 2026
Intensity Therapeutics, Inc. (INTS) is a healthcare company listed in the US with a market value of about $10M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -186%.
About Intensity Therapeutics
Intensity Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2023. It was profitable in 0 of the last 4 years in our data. Its share count rose by 894% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$12M | -$16M | -$11M | -$8M |
| Free cash flow | — | — | — | -$5M |
| EPS (diluted) | $-8.56 | $-29.24 | $-34.50 | $-55.50 |
| Net margin | — | — | — | — |
| ROIC | -78.9% | -428.7% | -49.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Intensity Therapeutics pay a dividend?
Not currently.
Is Intensity Therapeutics a good stock to buy?
We do not give buy or sell advice. Intensity Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.